Inhibition of Cisplatin-induced ATR Activity and Enhanced Sensitivity to Cisplatin
Overview
Affiliations
Ataxia teleangiectasia mutated (ATM) kinase, ATM-Rad3-related (ATR) kinase and DNA-protein kinase (DNA-PK) belong to a subgroup of protein kinases which play a role in the DNA damage response. In this study, cisplatin was shown to increase ATR activity and decrease ATM and DNA-PK activity. Caffeine, a nonspecific inhibitor of ATR, enhanced the cytotoxic effect of cisplatin, modestly decreased the p53 and p21WAF-1 response to cisplatin, and affected the cdc2-p34/cyclin B1 complex by decreasing both cyclin B1 protein accumulation and cdc2-p34 tyrosine 15 phosphorylation. The observed alteration of several potential ATR downstream targets suggests that inhibition of ATR activity may be one of the mechanism by which caffeine regulates sensitivity to cisplatin.
Galsky M, Guan X, Rishipathak D, Rapaport A, Shehata H, Banchereau R Cell Rep Med. 2024; 5(2):101393.
PMID: 38280376 PMC: 10897541. DOI: 10.1016/j.xcrm.2024.101393.
ATR Inhibition in Advanced Urothelial Carcinoma.
Leibrandt R, Tu M, Yu A, Lara P, Parikh M Clin Genitourin Cancer. 2023; 21(2):203-207.
PMID: 36604210 PMC: 10750798. DOI: 10.1016/j.clgc.2022.10.016.
Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy.
Ahmed S, Alam W, Aschner M, Alsharif K, Albrakati A, Saso L Biomed Pharmacother. 2022; 155:113797.
PMID: 36271573 PMC: 9590097. DOI: 10.1016/j.biopha.2022.113797.
Gomes L, Rocha C, Martins D, Fiore A, Sarti Kinker G, Bruni-Cardoso A Cell Death Dis. 2019; 10(6):459.
PMID: 31189884 PMC: 6561919. DOI: 10.1038/s41419-019-1689-8.
Targeting the ATR-CHK1 Axis in Cancer Therapy.
Rundle S, Bradbury A, Drew Y, Curtin N Cancers (Basel). 2017; 9(5).
PMID: 28448462 PMC: 5447951. DOI: 10.3390/cancers9050041.